

### ICD-10 MS-DRGs Version 42.1 Effective April 01, 2025

The Centers for Medicare & Medicaid Services (CMS) is implementing 50 new procedure codes into the International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), effective April 01, 2025.

The ICD-10 MS-DRG Grouper assigns each case into an MS-DRG based on the reported diagnosis and procedure codes and demographic information (age, sex, and discharge status).

The ICD-10 Medicare Code Editor (MCE) Version 42.1 software uses edits to detect and report errors in the claims data for the ICD-10 codes reported to validate correct coding on claims for discharges on or after April 01, 2025.

The ICD-10 MS-DRG Grouper software package to accommodate these 50 new codes, Version 42.1, is effective for discharges on or after April 01, 2025.

Assignment of the 50 new ICD-10-PCS procedure codes is as follows:

<b>Procedure Code</b>	<b>Description</b>	<b>O.R.</b>	<b>MDC</b>	<b>MS-DRG</b>
D228DZZ**	Stereotactic other photon radiosurgery of conduction mechanism	N	05	317
0B118D6*	Bypass trachea to esophagus with intraluminal device, via natural or artificial opening endoscopic	N		
0CYS0Z0	Transplantation of larynx, allogeneic, open approach	Y	03 04 21 24	143-145 166-168 907-909 957-959
0CYS0Z1	Transplantation of larynx, syngeneic, open approach	Y	03 04 21 24	143-145 166-168 907-909 957-959
0DX80Z7	Transfer small intestine to vagina, open approach	Y	13 21 24	748 907-909 957-959
0DX84Z7	Transfer small intestine to vagina, percutaneous endoscopic approach	Y	13 21 24	748 907-909 957-959
0TT00Z0	Resection of right kidney, open approach, allogeneic	Y	11 21 24	656-661 907-909 957-959
0TT00Z1	Resection of right kidney, open approach, syngeneic	Y	11 21 24	656-661 907-909 957-959
0TT00Z2	Resection of right kidney, open approach, zooplastic	Y	11 21 24	656-661 907-909 957-959

OTT10Z0	Resection of left kidney, open approach, allogeneic	Y	11 21 24	656-661 907-909 957-959
OTT10Z1	Resection of left kidney, open approach, syngeneic	Y	11 21 24	656-661 907-909 957-959
OTT10Z2	Resection of left kidney, open approach, zooplastic	Y	11 21 24	656-661 907-909 957-959
0U7C7DJ*	Dilation of cervix with intraluminal device, temporary, via natural or artificial opening	N		
10D10ZZ	Extraction of products of conception, retained, open approach	Y	14	770 796-798
3E0U0GC*	Introduction of other therapeutic substance into joints, open approach	N		
X2KA30A	Bypass left atrium using conduit through coronary sinus to right atrium, percutaneous approach, new technology group 10	Y	05 21	270-272 907-909
X2U93YA	Supplement right atrium with intraluminal device, heterotopic bioprosthetic valve(s), percutaneous approach, new technology group 10	Y	05	266-267
XNS40GA	Reposition right humeral shaft with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	492-494 907-909 957-959
XNS43GA	Reposition right humeral shaft with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	492-494 907-909 957-959
XNS50GA	Reposition left humeral shaft with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	492-494 907-909 957-959
XNS53GA	Reposition left humeral shaft with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	492-494 907-909 957-959
XNS60GA	Reposition right radius with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	510-512 907-909 957-959
XNS63GA	Reposition right radius with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	510-512 907-909 957-959
XNS70GA	Reposition left radius with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	510-512 907-909 957-959
XNS73GA	Reposition left radius with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	510-512 907-909 957-959

XNS80GA	Reposition right ulna with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	510-512 907-909 957-959
XNS83GA	Reposition right ulna with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	510-512 907-909 957-959
XNS90GA	Reposition left ulna with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	510-512 907-909 957-959
XNS93GA	Reposition left ulna with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	510-512 907-909 957-959
XNSA0GA	Reposition right upper femur with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	480-482 907-909 956
XNSA3GA	Reposition right upper femur with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	480-482 907-909 956
XNSB0GA	Reposition left upper femur with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	480-482 907-909 956
XNSB3GA	Reposition left upper femur with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	480-482 907-909 956
XNSC0GA	Reposition right lower femur with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	480-482 907-909 956
XNSC3GA	Reposition right lower femur with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	480-482 907-909 956
XNSD0GA	Reposition left lower femur with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	480-482 907-909 956
XNSD3GA	Reposition left lower femur with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	480-482 907-909 956
XNSE0GA	Reposition right femoral shaft with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	480-482 907-909 956
XNSE3GA	Reposition right femoral shaft with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	480-482 907-909 956
XNSF0GA	Reposition left femoral shaft with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	480-482 907-909 956

XNSF3GA	Reposition left femoral shaft with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	480-482 907-909 956
XNSG0GA	Reposition right tibia with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	492-494 907-909 957-959
XNSG3GA	Reposition right tibia with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	492-494 907-909 957-959
XNSH0GA	Reposition left tibia with ring external fixation device with automated strut adjustment, open approach, new technology group 10	Y	08 21 24	492-494 907-909 957-959
XNSH3GA	Reposition left tibia with ring external fixation device with automated strut adjustment, percutaneous approach, new technology group 10	Y	08 21 24	492-494 907-909 957-959
XW033MA*	Introduction of emapalumab-lzsg anti-IFN $\gamma$ monoclonal antibody into peripheral vein, percutaneous approach, new technology group 10	N		
XW033NA*	Introduction of tarlatamab-dlle antineoplastic into peripheral vein, percutaneous approach, new technology group 10	N		
XW043MA*	Introduction of emapalumab-lzsg anti-IFN $\gamma$ monoclonal antibody into central vein, percutaneous approach, new technology group 10	N		
XW043NA*	Introduction of tarlatamab-dlle antineoplastic into central vein, percutaneous approach, new technology group 10	N		
XXE5X5A*	Measurement of immune response, whole blood cellular assessment via microfluidic deformability, new technology group 10	N		

\*As the procedure codes are designated as non-O.R. procedures, there is no assigned MDC or MS-DRG. The ICD-10 MS-DRG assignment is dependent on the reported principal diagnosis, any secondary diagnoses defined as a complication or comorbidity (CC) or major complication or comorbidity (MCC), procedures or services performed, age, sex, and discharge status.

\*\*Non-O.R. procedure affecting the MS-DRG assignment.

The ICD-10 MS-DRG V42.1 Grouper Software, Definitions Manual Table of Contents and the Definitions of Medicare Code Edits V42.1 manual will be available at <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.html>

The Code Tables, Index and related Addenda files for the 50 new procedure codes will be available at: <https://www.cms.gov/medicare/coding-billing/icd-10-codes>